The complaint cites one count of infringement in regard to the ‘743 patent. The complaint asserts that the defendant’s VitalPatch meets every claim of the ‘743 patent, meaning that the defendant has “indirectly infringed” on the patent-in-suit by “actively and knowingly inducing patients to use the VitalPatch.” The defendant has allegedly been aware of their purported infringement since the filing of the Complaint.
#Bardy diagnostics inc skin#
VitalPatch is a wearable device intended to collect data regarding a patients “heart rate, electrocardiographic signals, respiratory rate, body temperature, skin temperature, and activity such as step count.”
#Bardy diagnostics inc Bluetooth#
The defendant’s product, VitalPatch, is said to include a Bluetooth transmitter.
#Bardy diagnostics inc Patch#
The ‘743 patent claims the CAM patch as an electrocardiography monitor with Bluetooth abilities and the ability to capture and store electrocardiographic signals. 11,051,743 (the ‘743 patent), which was issued in mid-2021.īardy alleges that the defendant, VitalConnect, is infringing on the aforementioned patent by manufacturing and marketing their product under the names “VitalPatch or VitalConnect Sensor, including without limitation the VitalPatch Biosensor, VitalPatch 1.0, VitalPatch1.5, VitalPatch 2.0, VitalPatch RTM, and/or any other versions thereof.” The suit comes following allegations that the defendant infringed on the plaintiff’s patents when they began manufacturing and marketing their VitalPatch product.īardy is the “developer of an industry leading electrocardiography monitor called the CAM patch.” The rights, title, and interest of the monitor is protected by U.S. The proprietary technology of the CAM patch provides optimal detection and clear recording of the P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis.Friday saw the filing of a complaint in the District of Delaware by Bardy Diagnostics, Inc. The CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. Bardy, MD, Founder and Chief Executive Officer, and Mark Handfelt, Chief Operating Officer, BardyDx provides Carnation Ambulatory Monitor, a P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device designed to improve patient compliance for adults and children weighing more than 10kg (22lbs). The company intends to use the funds to further accelerate growth of its innovative P-wave focused cardiac monitoring platform through expansion of the sales force and monitoring services, and to support advanced development programs, including augmented intelligence and visualization technologies. In conjunction with the funding, Rik Vandevenne, Managing Director of River Cities Capital Funds, and Garheng Kong, Managing Director of HealthQuest Capital, will join BardyDx’ board of directors. The round was led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures, and Rex Health Ventures and existing investors SV Health Investors, Health Enterprise Partners, and Ascension Ventures. Bardy Diagnostics, Inc., a Seattle, WA-based provider of ambulatory cardiac monitoring technologies and custom data solutions, raised $35.5m in Series B funding.
0 kommentar(er)
